Cisatracurium Besylate injection USP is a nondepolarizing skeletal neuromuscular blocker, indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgical procedures.

According to IQVIA (IMS Health), Cisatracurium Besylate Injection USP had US sales of approximately $35 million for the 12 month period ending December 2022.

C. C. Paarthipan, chairman of Caplin Point Laboratories, said, “We've been consistent with our filings and also happy to receive approvals on time. We're creating a healthy portfolio of products that we will launch not only in the US but in global markets as well. This approval will augment our growth plans for Caplin Steriles this year and the years going forward.”

Caplin Point Laboratories is engaged in the business of pharmaceuticals - producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.

The company's consolidated net profit jumped 29.2% to Rs 102.11 crore in Q4 FY23 as compared with Rs 79.06 crore in Q4 FY22. Net sales rose 14.8% year on year to Rs 389.28 crore in Q4 FY23 over Q4 FY22.